ENGAGE run · 803da074a8e2

```json [ { "post_index": 4, "cluster_ids": [16], "claim": "Federal funding enabling rural health infrastructure equipment modernization improves care access", "argument_type": "policy_argument", "stance": "supports_status_quo", "hyde_excerpt": "Rural health infrastructure funding represents a critical but underutilized policy lever for addressing geographic disparities i

```json [ { "post_index": 12, "matched_article_id": 483, "match_confidence": 87, "match_reason": "The tweet describes a patient harmed by prior authorization delay caused by an insurer information gap (criteria met but authorization denied/delayed), directly matching the article's thesis that prior auth is an information problem — specifically that no one knows the rules at the m

The harm here is real and the outrage is justified. But the mechanism causing it is more specific than "insurer delays," and getting that wrong means the solutions people build keep missing. The six weeks of conservative therapy requirement your post references is almost never in the main payer's policy document. It lives in a separate clinical guideline published by a delegated utilization manag

The $56M figure is worth sitting with for a second. That's Texas drawing from RHTP's five-year allocation, which the statute caps at $281M total for the state, and equipment modernization is only one of six eligible use categories. So the question isn't whether this is real money, it's whether HHSC has the architecture to move it efficiently. And that's where the friction lives. Texas has 88 Crit

The financial incentive problem you're describing is real, but the generic drug trial gap is actually a symptom of something deeper than just patent status. When I looked at Revlimid's economics for a piece on pharmaceutical pricing, the numbers made the structural logic plain: Celgene generated over $100 billion in sales on roughly $800 million in development costs, with pills that cost about 25

The adoption signal is real. But the "how well it works" debate often collapses two separate questions that procurement teams and investors need to keep apart: does the model perform well on benchmarks, and does the model perform well when embedded in actual clinical workflow? Those aren't the same question, and the gap between them is where most clinical AI deployments quietly fail. The DeepSee

```json [] ```

[]

```json [ {"post_index": 0, "prediction": "reject", "confidence": 95, "reason": "weather report unrelated to healthcare"}, {"post_index": 1, "prediction": "reject", "confidence": 95, "reason": "retail/membership policy unrelated to healthcare"}, {"post_index": 2, "prediction": "reject", "confi

```json [ { "category": "ai_safety_vulnerability_tangent_no_healthcare_context", "summary": "Posts about AI safety vulnerabilities, agent hacking, or security incidents presented without healthcare system implications or applications.", "exclusion_rule": "Exclude posts that focus on AI